William Blair Lowers Earnings Estimates for Evolent Health

Evolent Health, Inc. (NYSE:EVH - Free Report) - Research analysts at William Blair lowered their Q4 2024 earnings per share (EPS) estimates for Evolent Health in a research note issued to investors on Thursday, January 30th. William Blair analyst R. Daniels now expects that the technology company will earn ($0.06) per share for the quarter, down from their prior forecast of ($0.05). The consensus estimate for Evolent Health's current full-year earnings is $0.24 per share.

Evolent Health (NYSE:EVH - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The technology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The company had revenue of $621.40 million for the quarter, compared to analysts' expectations of $625.58 million. During the same period last year, the business earned $0.19 earnings per share.

Several other research analysts also recently commented on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Evolent Health from $15.00 to $13.00 and set an "overweight" rating for the company in a report on Tuesday, January 28th. Stephens decreased their price objective on Evolent Health from $16.00 to $12.00 and set an "equal weight" rating on the stock in a report on Tuesday, January 21st. Citigroup lowered their price objective on shares of Evolent Health from $21.00 to $18.00 and set a "buy" rating for the company in a research report on Friday, January 10th. Barclays reduced their price objective on Evolent Health from $39.00 to $19.00 and set an "overweight" rating on the stock in a research note on Monday, November 11th. Finally, Truist Financial decreased their price target on Evolent Health from $20.00 to $15.00 and set a "buy" rating on the stock in a report on Wednesday, January 22nd. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $18.38.

Evolent Health Price Performance

Shares of NYSE:EVH traded down $0.58 during midday trading on Monday, reaching $9.79. 2,045,390 shares of the company were exchanged, compared to its average volume of 2,176,191. The stock has a market cap of $1.14 billion, a PE ratio of -10.75 and a beta of 1.45. The business's fifty day moving average is $11.11 and its two-hundred day moving average is $19.77. Evolent Health has a one year low of $9.74 and a one year high of $35.00. The company has a current ratio of 1.04, a quick ratio of 1.04 and a debt-to-equity ratio of 0.58.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in EVH. Raymond James Financial Inc. purchased a new stake in shares of Evolent Health in the 4th quarter worth approximately $2,542,000. WoodTrust Financial Corp boosted its holdings in shares of Evolent Health by 28.7% in the 4th quarter. WoodTrust Financial Corp now owns 54,900 shares of the technology company's stock valued at $618,000 after buying an additional 12,250 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Evolent Health by 0.7% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 918,992 shares of the technology company's stock valued at $10,339,000 after acquiring an additional 6,597 shares in the last quarter. Levin Capital Strategies L.P. purchased a new position in Evolent Health in the fourth quarter worth $664,000. Finally, Parkside Financial Bank & Trust increased its position in shares of Evolent Health by 90.7% during the fourth quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company's stock worth $56,000 after purchasing an additional 2,358 shares in the last quarter.

About Evolent Health

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.